{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:13:44Z","timestamp":1783660424727,"version":"3.55.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Malignant melanoma is the most aggressive form of skin cancer, with increasing incidence and a high risk of metastasis and mortality. While conventional treatments such as surgery, immunotherapy, and targeted therapy remain standard, interest in integrative naturopathic oncology approaches is growing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case representation<\/jats:title>\n                    <jats:p>Case 1 is a woman in her early 60s who was initially diagnosed with malignant melanoma of the lower back in the early 1990s at age 30. This was treated with surgical excision alone, after which she remained in remission for nearly 2 decades. Between 2011 and 2018, she experienced multiple recurrences in the left axilla, paraspinal lumbar tissue, and gastric fundus. She underwent surgery for these recurrences and received stereotactic body radiation therapy (SBRT) to the spinal disease. Following each recurrence, she declined systemic therapy and pursued adjuvant naturopathic treatment cycles including fever-range whole-body hyperthermia (FR-WBHT), modulated electro-hyperthermia (mEHT), intravenous pharmacologic ascorbic acid, mistletoe therapy, repurposed drugs, and oral supplementation. Since her last recurrence in 2018, she has remained in clinical remission, with follow-up PET imaging through 2026 showing no evidence of disease.<\/jats:p>\n                    <jats:p>Case 2 is a 65-year-old woman with recurrent melanoma, with metastases to the brain, liver, and lymph nodes. When no conventional treatment options were offered, she pursued naturopathic therapies including hyperthermia (mEHT, FR-WBHT), intravenous pharmacologic ascorbic acid, mistletoe therapy, repurposed drugs, and targeted supplementation. Imaging revealed gradual reductions in tumor size during treatment, marked by progressive decrease in masses. This resulted in complete remission by 2017, which remains in 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These cases describe prolonged remission temporally associated with multimodal integrative naturopathic oncology care in two cases of metastatic melanoma who also underwent surgery and\/or radiotherapy. Alongside surgery, patients received hyperthermia, mistletoe extract, intravenous vitamin C, targeted pharmaceutical agents, and individualized supplementation. Both patients demonstrated regression of metastatic lesions with no detectable disease on imaging. Larger clinical studies are needed to further evaluate the safety and potential therapeutic effects of this approach in melanoma patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1867929","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:24:32Z","timestamp":1783657472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An integrative naturopathic oncology approach in metastatic malignant melanoma: two case reports"],"prefix":"10.3389","volume":"16","author":[{"given":"Sara","family":"Izadi-Najafabadi","sequence":"first","affiliation":[{"name":"Research Department, The Parmar Foundation","place":["White Rock, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Moffatt","sequence":"additional","affiliation":[{"name":"Research Department, Integrated Health Clinic","place":["Surrey, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Neufeld","sequence":"additional","affiliation":[{"name":"Research Department, Integrated Health Clinic","place":["Surrey, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdev","family":"Parmar","sequence":"additional","affiliation":[{"name":"Research Department, The Parmar Foundation","place":["White Rock, BC, Canada"]},{"name":"Research Department, Integrated Health Clinic","place":["Surrey, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","volume-title":"American Cancer Society","year":"2025"},{"key":"B2","unstructured":"Canadian Cancer Statistics 2024\n          \n          \n          \n          2024"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1268479","article-title":"Advances in melanoma: epidemiology, diagnosis, and prognosis","volume":"10","author":"Waseh","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.11S1a161S","article-title":"Epidemiology and risk factors of melanoma: a review","volume":"11","author":"Conforti","year":"2021","journal-title":"Dermatol Pract Concept"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103754","article-title":"Current knowledge of immunosuppression as a risk factor for skin cancer development","volume":"177","author":"Rollan","year":"2022","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","author":"Davis","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02272","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/nejmoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100788","article-title":"Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy","volume":"8","author":"Gouda","year":"2023","journal-title":"ESMO Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad300","article-title":"Clinical predictors of survival in patients with BRAFV600-mutated metastatic melanoma treated with combined BRAF and MEK inhibitors after immune checkpoint inhibitors","volume":"29","author":"Kahn","year":"2024","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5967","article-title":"Health\u2010related quality of life in survivors of advanced melanoma treated with anti\u2010PD1\u2010based immune checkpoint inhibitors","volume":"12","author":"Looman","year":"2023","journal-title":"Cancer Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-023-01507-w","article-title":"Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review","volume":"19","author":"G\u00fcven","year":"2024","journal-title":"J Cancer Survivorship"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12123946","article-title":"Integrative oncology and the clinical care network: challenges and opportunities","volume":"12","author":"Semeniuk","year":"2023","journal-title":"J Clin Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgx012","article-title":"A comprehensive definition for integrative oncology","volume":"2017","author":"Witt","year":"2017","journal-title":"J Natl Cancer Institute Monogr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12906-022-03556-7","article-title":"Operational definition of complementary, alternative, and integrative medicine derived from a systematic search","volume":"22","author":"Ng","year":"2022","journal-title":"BMC Complementary Med Ther"},{"key":"B20","unstructured":"Care Case Report Guidelines"},{"key":"B21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-023-09876-7","article-title":"Pathological angiogenesis: mechanisms and therapeutic strategies","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1040163","article-title":"Chronic inflammation, cancer development and immunotherapy","volume":"13","author":"Wen","year":"2022","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119942","article-title":"Reactive oxygen species: role in carcinogenesis, cancer cell signaling and tumor progression","volume":"284","author":"Sarmiento-Salinas","year":"2021","journal-title":"Life Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7180\/kmj.24.127","article-title":"Current understanding of modulated electro-hyperthermia in cancer treatment","volume":"39","author":"Kim","year":"2024","journal-title":"Kosin Med J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020346","article-title":"A review of the current clinical evidence for loco-regional moderate hyperthermia in the adjunct management of cancers","volume":"15","author":"Chia","year":"2023","journal-title":"Cancers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)90463-8","article-title":"Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic Malignant melanoma","volume":"345","author":"Overgaard","year":"1995","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-8140(86)80016-0","article-title":"Combined treatment with radiation and hyperthermia inmetastatic Malignant melanoma","volume":"6","author":"Gonzalez","year":"1986","journal-title":"Radiotherapy Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10724","DOI":"10.1038\/s41598-018-29018-0","article-title":"Hyperthermia induces therapeutic effectiveness and potentiates adjuvant therapy with non-targeted and targeted drugs in an in vitro model of human Malignant melanoma","volume":"8","author":"Mantso","year":"2018","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"101024","DOI":"10.2139\/ssrn.5276164","article-title":"Efficacy of radiotherapy and radiotherapy with hyperthermia to delay change of systemic therapy in patients with metastatic melanoma","volume":"55","author":"Chmiel","year":"2025","journal-title":"Clin Trans Radiat Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123872","article-title":"Suppression of metastatic melanoma growth in lung by modulated electro-hyperthermia monitored by a minimally invasive heat stress testing approach in mice","volume":"12","author":"Thomas","year":"2020","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251316189","article-title":"Radiotherapy combined with locoregional hyperthermia for oligoprogression in metastatic melanoma local control","volume":"17","author":"Borkowska","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22654","article-title":"Vitamin C at high concentrations induces cytotoxicity in Malignant melanoma but promotes tumor growth at low concentrations","volume":"56","author":"Yang","year":"2017","journal-title":"Mol Carcinog"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5893017","article-title":"Mistletoe and immunomodulation: insights and implications for anticancer therapies","volume":"2019","author":"Oei","year":"2019","journal-title":"Evidence-Based Complementary Altern Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.595207","article-title":"Hyperthermia targeting the tumor microenvironment facilitates immune checkpoint inhibitors","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/1534735414534463","article-title":"Intravenous vitamin C and cancer: a systematic review","volume":"13","author":"Fritz","year":"2014","journal-title":"Integr Cancer Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"987527","DOI":"10.1155\/2014\/987527","article-title":"Mistletoe: from basic research to clinical outcomes in cancer and other indications","volume":"2014","author":"Kr\u00f6z","year":"2014","journal-title":"Evidence-Based Complementary Altern Medicine: eCAM"},{"key":"B38","first-page":"412186","article-title":"Critical analysis of electromagnetic hyperthermia randomized trials: dubious effect and multiple biases","author":"Roussakow","year":"2013"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000000526","article-title":"Spontaneous regression of Malignant melanoma-is it based on the interplay between host immune system and melanoma antigens","volume":"28","author":"Cervinkova","year":"2017","journal-title":"Anti-cancer Drugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3109\/00313027509092702","article-title":"Spontaneous regression of melanoma","volume":"7","author":"McGovern","year":"1975","journal-title":"Pathology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3747\/co.20.1212","article-title":"Spontaneous regression of metastatic melanoma after inoculation with tetanus\u2013diphtheria\u2013pertussis vaccine","volume":"20","author":"Tran","year":"2013","journal-title":"Curr Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejso.2013.09.026","article-title":"Spontaneous regression of metastatic melanoma\u2013clinical evidence of the abscopal effect","volume":"40","author":"Bramhall","year":"2014","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-026-02792-2","article-title":"Stereotactic body radiation therapy for oligometastatic melanoma: a real-world study of the ESTRO\/EORTC nomenclature","volume":"21","author":"Heurlin","year":"2026","journal-title":"Radiat Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1322515","article-title":"Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study","volume":"14","author":"Trentesaux","year":"2024","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcskn.2025.100523","article-title":"Long-term outcomes of melanoma oligoprogressive metastases treated with radiotherapy combined with locoregional hyperthermia","author":"Borkowska","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176270","article-title":"Modulated electro-hyperthermia-induced tumor damage mechanisms revealed in cancer models","volume":"21","author":"Krenacs","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2017.1335440","article-title":"Role of HIF-1\u03b1 in response of tumors to a combination of hyperthermia and radiation in vivo","volume":"34","author":"Kim","year":"2018","journal-title":"Int J Hyperthermia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1487296","article-title":"From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy","volume":"16","author":"Abreu","year":"2025","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctim.2018.03.009","article-title":"Fever as a factor contributing to long-term survival in a patient with metastatic melanoma: a case report","volume":"38","author":"Wrotek","year":"2018","journal-title":"Complementary Therapies Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1364128","article-title":"Fever of unknown origin associated with immune checkpoint inhibitors","volume":"15","author":"Tong","year":"2024","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000000655","article-title":"Dabrafenib and trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection","volume":"29","author":"Clay","year":"2018","journal-title":"Anti-Cancer Drugs"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cells11071229","article-title":"Therapeutic efficacy of pharmacological ascorbate on braf inhibitor resistant melanoma cells in vitro and in vivo","volume":"11","author":"Niessner","year":"2022","journal-title":"Cells"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/284629a0","article-title":"Vitamin C preferential toxicity for Malignant melanoma cells","volume":"284","author":"Bram","year":"1980","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47080672","article-title":"Mistletoe in cancer cell biology: Recent advances","volume":"47","author":"Hong","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12906-020-03013-3","article-title":"Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis","volume":"20","author":"Loef","year":"2020","journal-title":"BMC Complementary Med Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2007.6175","article-title":"Successful treatment of metastatic Malignant melanoma with Viscum album extract (Iscador\u00ae M)","volume":"13","author":"Kirsch","year":"2007","journal-title":"J Altenative Complementary Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000008731","article-title":"Complete remission and long-term survival of a patient with melanoma metastases treated with high-dose fever-inducing Viscum album extract: a case report","volume":"96","author":"Werthmann","year":"2017","journal-title":"Medicine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-45588-w","article-title":"Early detection of metastatic risk in primary cutaneous melanoma using weakly supervised learning","volume":"16","author":"Dahl\u00e9n","year":"2026","journal-title":"Sci Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1867929\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:24:33Z","timestamp":1783657473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1867929\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":58,"alternative-id":["10.3389\/fonc.2026.1867929"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1867929","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1867929"}}